News from viiv healthcare A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 20, 2018, 12:24 ET ViiV Healthcare anuncia novos dados positivos para o dolutegravir no tratamento de pessoas vivendo com HIV coinfectadas com tuberculose

A ViiV Healthcare, a empresa especialista global em HIV, de propriedade majoritária da GlaxoSmithKline com a Pfizer Inc. e Shionogi Limited como...


Mar 05, 2018, 12:00 ET ViiV Healthcare anuncia nuevos datos positivos sobre dolutegravir para el tratamiento de personas coinfectadas por el VIH y tuberculosis

ViiV Healthcare, la compañía global especializada en VIH, cuyo propietario mayoritario es GlaxoSmithKline, con Pfizer Inc. y Shionogi Limited como...


Nov 21, 2017, 18:45 ET Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today...


Jul 25, 2017, 09:03 ET ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings

DAWNING study modified to allow patients the opportunity to receive dolutegravir-based regimens ViiV Healthcare, the global specialist HIV company,...


Aug 16, 2016, 08:55 ET ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment

ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®)...


Jul 18, 2016, 06:15 ET ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy...


Jun 10, 2016, 09:15 ET ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV

Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that ...


Feb 24, 2016, 12:12 ET ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented...


Feb 23, 2016, 02:49 ET ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen ViiV...


Jan 19, 2016, 08:30 ET ViiV Healthcare & the Los Angeles Department of Health Services Announce New Fellowship Program to Address a Growing Shortage of Primary Care HIV Specialists

ViiV Healthcare and the Los Angeles Department of Health Services (LA DHS) today announced the launch of the ViiV Healthcare/LA DHS HIV Public Health ...


Jan 07, 2016, 08:31 ET ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today formalised its collaboration with...


Nov 03, 2015, 08:24 ET ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study ...


Oct 26, 2015, 10:27 ET ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally

ViiV Healthcare today awarded its first round of small grants to support men who have sex with men (MSM) and transgender community-led interventions...


Sep 23, 2015, 05:27 ET New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression

ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and...


Jul 02, 2015, 03:00 ET ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries

Agreement reinforces ViiV Healthcare commitment to improving access to HIV treatments ViiV Healthcare and Desano Pharmaceuticals (Desano) today...


May 26, 2015, 09:00 ET ViiV Healthcare and CHAI Collaboration Delivers Second Milestone With First Filing With the FDA of Generic Dolutegravir by Aurobindo Pharma for the Treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an...


May 06, 2015, 04:51 ET ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine ViiV Healthcare today announced the start of a Phase III...


Feb 04, 2015, 09:30 ET ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men

ViiV Healthcare today announced the launch of a four-year, $10 million initial investment to fuel a concerted community response to the HIV epidemic...


Dec 04, 2014, 11:29 ET Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug...


Oct 20, 2014, 09:00 ET ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.

ViiV Healthcare today announced seven Positive Action Southern Initiative grant awardees in Georgia, Louisiana and Mississippi for programs focused...


Aug 25, 2014, 09:00 ET Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq® (abacavir 600mg, dolutegravir 50mg and...


Aug 25, 2014, 07:32 ET ViiV Healthcare recibe aprobación de la FDA para Triumeq® (abacavir, dolutegravir y lamivudine), una nueva régimen de tableta única para el tratamiento de la infección por VIH-1

El 22 de agosto, ViiV Healthcare anunció que la Administración de Alimentos y Medicamentos de EE. UU. (FDA) ha aprobado Triumeq® comprimidos (600 mg...


Aug 22, 2014, 03:46 ET ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and...


Jun 14, 2014, 01:59 ET ViiV Healthcare annonce un nouveau projet de collaboration avec Janssen en vue de mettre au point un comprimé unique destiné au traitement d'entretien des patients contaminés par le VIH-1

ViiV Healthcare a annoncé aujourd'hui la signature d'un accord avec Janssen R&D Ireland Ltd (Janssen) dans le cadre de la mise au point et de la...


Jun 14, 2014, 01:53 ET ViiV Healthcare meldet neue Kooperation mit Janssen zwecks Untersuchung eines Einzeltablettenpräparats für die Erhaltungstherapie bei HIV-1

ViiV Healthcare gab heute bekannt, dass das Unternehmen mit Janssen R&D Ireland Ltd (Janssen) eine Vereinbarung zur gemeinsamen Entwicklung und...